
Karl Peggs to be Chief Medical Officer for Achilles Therapeutics
Achilles Therapeutics will officially bring Professor Karl Peggs on as Chief Medical Officer on January 4, 2021. Karl founded Achilles Therapeutics, utilizing his extensive knowledge and experience in the field of cancer immunology. Currently, Karl is Professor of Transplant Science and Cancer Immunotherapy at University College London Cancer Institute. He is also Scientific Director of the National Institute for Health Research Blood and Transplant Research Unit for Stem Cells and Immunotherapies, and Clinical and Scientific Director of the Sir Naim Dangoor Centre for Cellular Immunotherapy at University College London Hospitals.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer based in Stevenage, UK.